Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Merkel Cell 2Melanoma 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × domatinostat × Dermatologic × Clear all
NCT04393753 2024-05-08

MERKLIN2

4SC AG

Phase 2 Completed
19 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT03278665 2022-02-04

SENSITIZE

4SC AG

Phase 1/2 Completed
40 enrolled
Dermatologic

Melanoma

NCT04874831 2021-11-18

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

4SC AG

Phase 2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡